The Future of Biosimilars

International Journal of Drug Delivery

View Publication Info
Field Value
Title The Future of Biosimilars
Creator El-Bakry, L; The George Washington University School of Medicine, Regulatory Affairs Program, 2121 I St NW, Washington, DC 20052, USA
Subject Pharmaceutical Sciences; Pharmaceutics; Drug Delivery
Biosimilars; generic drugs; quality improvement; ecosystem; BPCI Act.
Description Biosimilars are to Biologic products what generic drugs are to chemical products, a more affordable solution to the increasing drug pricing without sacrificing the quality of the treatment.There is much debate in the health care industry as to whether Biosimilars will deliver on the same success achieved by the generic products, which can amount to up to 80% in some cases.   It is my view though that Biosimilars provide a viable path to cost reduction, quality improvement and affordable accessibility to medication.  In fact, the introduction of lower costs Biologics as intended by the Biosimilar market will force competition within the therapeutics treatment market that will both exertpricing pressure as well as inspire innovation in the entire ecosystem. 
Publisher Advanced Research Journals
Date 2017-06-21
Type info:eu-repo/semantics/article

Format application/pdf
Source International Journal of Drug Delivery; Vol 9, No 1 (2017): International Journal of Drug Delivery; 01-02
Language eng
Rights Copyright (c) 2017 L. El-Bakry

Contact Us

The PKP Index is an initiative of the Public Knowledge Project.

For PKP Publishing Services please use the PKP|PS contact form.

For support with PKP software we encourage users to consult our wiki for documentation and search our support forums.

For any other correspondence feel free to contact us using the PKP contact form.

Find Us


Copyright © 2015-2018 Simon Fraser University Library